Back to search

Switzerland· 67983002

Vesoxx 1 mg/ml, Lösung zur intravesikalen Anwendung

A oxybutynin product containing oxybutyninum, registered in Switzerland by Melisana AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 18 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat B (Swissmedic)ATC G04BD04

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedVesoxx 1 mg/ml, Lösung zur intravesik…ATCG04BD04REGISTER NO.67983002PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Oxybutynin is registered in 18 of 19 countries.

Countries holding a registration under ATC G04BD04 (oxybutynin), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 10 of them publish a price we can compare per daily dose

Oxybutynin · ATC G04BD04

18 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of oxybutynin costs, country by country.

Normalised to the WHO defined daily dose (15 mg), the median price runs from $0.17 in France to $2.99 in Switzerland — a ×18 gap.

  • Switzerland: $2.99 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail

Oxybutynin · price per daily dose (15 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$2.99
  • IT Italy$0.59
  • US United States$0.20 (acquisition cost)
  • FR France$0.17
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

Swissmedic (Switzerland)
Active substance
oxybutyninum
Manufacturer
Melisana AG
Country
Switzerland (CH)
ATC code
G04BD04
ATC class
Oxybutynin
Defined daily dose
15 mg, O
Swissmedic category
B
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680679830028
    100 Fertspr 10 ml
    CHF 1220.6

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

312 interactions on record for oxybutynin.

Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Oxybutynin · interactions on record

312 records

  • 3 severe
  • 103 moderate
  • 1 minor
  • 168 info

Most severe, free to view

  • Potassium chlorideA12BA01severe
  • Potassium citrateA12BA02severe
  • Potassium chlorideB05XA01severe
  • DicycloverineA03AA07moderate

37 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Oxybutynin in 17 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All oxybutynin products

Authorised across Europe · EMA

The same active substance is authorised in 27 EEA countries. Names it is sold under:

  • Austria · Detrusan, Ditropan
  • Belgium · Oxybutynine Eg, Velariq
  • Bulgaria · Дриптан
  • Czechia · Tarraconiq, Uroxal
  • Germany · Dridase, Oxybutynin Aaa-Pharma
  • Denmark · Oxybutynin Macure, Oxybutynin Unimedic
  • Estonia · Driptane
  • Spain · Ditropan, Dresplan
  • Finland · Oxybutynin Macure, Oxybutynin Unimedic
  • France · Ditropan, Oxybutynine Accord
  • United Kingdom (Northern Ireland) · Ditropan, Oxybutynin Hydrochloride
  • Greece · Ditropan
  • Hungary · Ditropan, Uroxal
  • Ireland · Oxybutynin Hydrochloride Accord Healthcare Ireland, Oxybutynin Hydrochloride Syri Pharma
  • Iceland · Kentera
  • Italy · Ditropan, Ossibutinina Cloridrato Mylan Generics
  • Liechtenstein · Kentera
  • Lithuania · Driptane
  • Luxembourg · Oxybutynine Eg, Velariq
  • Latvia · Driptane
  • Netherlands · Dridase, Oxybutinin Hydrochloride Aurobindo
  • Norway · Kentera, Oxybutynin Macure
  • Poland · Ditropan, Driptane
  • Portugal · Ditropan, Velariq
  • Romania · Driptane
  • Sweden · Ditropan, Oxybutynin Accord
  • Slovakia · Uroxal, Velariq

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/29f94022-227a-43fa-95e3-cd62ea6d1d99
GET /v1/drugs/29f94022-227a-43fa-95e3-cd62ea6d1d99?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "oxybutynini hydrochloridum 10.04 mg",
  "valid_from": "2025-09-01",
  "limitations": "[{\"description\":\"Vesoxx wird vergütet zur Unterdrückung einer neurogenen Detrusorüberaktivität (Neurogenic Detrusor Overactivity: NDO) bei Kindern ab 6 Jahren und bei Erwachsenen, die ihre Blase mittels sauberer intermittierender Katheterisierung entleeren, wenn sie durch eine Behandlung mit oralen Anticholinergika aufgrund mangelnder Wirksamkeit und/oder unerträglicher Nebenwirkungen nicht adäquat eingestellt werden können.<br>\\nDie Erstverordnung und die erstmalige Dosisanpassung muss von einem Neuro-Urologen unter engmaschiger urodynamischer Kontrolle durchgeführt werden.<br>\\nVESOXX wird nach Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes vergütet.<br>\\n<br>\\nDie Melisana AG vergütet dem Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, auf dessen erste Aufforderung hin für auf jede bezogene Packung VESOXX einen festgelegten Anteil des Fabrikabgabepreises zurück. Sie gibt dem Krankenversicherer die Höhe der Rückvergütung bekannt. Die Mehrwertsteuer kann nicht zusätzlich zu diesem Anteil des Fabrikabgabepreises zurückgefordert werden. Die Aufforderung zur Rückvergütung soll ab dem Zeitpunkt der Verabreichung erfolgen.<br>\\nFolgender Indikationscode ist an den Krankenversicherer zu übermitteln: 21242.01<br>\\n<br>\",\"costApproval\":null,\"indication\":\"21242.01\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2025-09-01\",\"validTo\":\"2028-08-31\"}]",
  "galenic_form": "Lös 10 mg/10ml",
  "therapeutic_area": null,
  "sl_inclusion_date": "2024-11-01",
  "self_retention_pct": 10
}

See everything about oxybutynin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.